Peripheral Intravascular Ultrasound Catheter Market By Product Type (20 MHz Catheters, 40 MHz Catheters, Hybrid Catheters); By Application (Peripheral Artery Disease, Aneurysm and Venous Interventions, Others); By End User (Hospitals, Catheterization Labs, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Peripheral Intravascular Ultrasound Catheter Market will witness a robust CAGR Of 10.4%, valued at USD 1.1 billion in 2024 , and is expected to reach USD 2.0 billion by 2030 , according to Strategic Market Research.

 

This segment, though niche compared to broader imaging modalities, is gaining strategic relevance for vascular diagnostics and intervention. Peripheral IVUS catheters provide real-time cross-sectional imaging inside blood vessels — especially arteries in the legs and arms. Their primary role? Guiding endovascular procedures by visualizing vessel walls, plaque morphology, and lumen size more precisely than angiography alone.

 

Between 2024 and 2030, the market is accelerating on two parallel fronts: clinical demand and technological evolution. Rising global incidence of peripheral artery disease (PAD) — now affecting over 230 million people — is pushing clinicians to adopt tools that go beyond surface-level diagnostics. In procedures like angioplasty or stent placement, IVUS is emerging as a key enabler for precision therapy.

 

Simultaneously, device makers are innovating faster. Catheters are getting smaller, more flexible, and equipped with high-resolution arrays. Integration with digital platforms and hybrid imaging tools is transforming these devices from basic diagnostic accessories into dynamic, data-rich instruments that inform decisions on the table.

 

Clinicians aren’t the only drivers. Payers are beginning to recognize the long-term cost benefits of IVUS-guided procedures, which reduce repeat interventions and adverse outcomes. In the U.S., updated reimbursement codes are encouraging wider use, especially in complex or high-risk patients. Meanwhile, interventionalists in Europe and Japan are shifting from a “stent-first” mindset to a “visualize-and-treat” workflow, which favors IVUS.

 

There’s also a subtle shift in mindset. Peripheral vascular disease, once overshadowed by coronary care, is now a growing public health concern. With aging populations, diabetes prevalence, and lifestyle risk factors on the rise, the peripheral imaging landscape is evolving. Hospitals, catheterization labs, and even outpatient centers are seeing value in stocking IVUS systems for vascular access, limb salvage, and post-angioplasty assessment.

 

The stakeholder ecosystem is wide — from original equipment manufacturers (OEMs) developing dual-mode IVUS-Optical Coherence Tomography (OCT) systems, to vascular surgeons seeking real-time feedback, to healthcare administrators looking for technology that reduces procedural variability. Even investors are starting to see peripheral IVUS not just as a surgical tool, but as part of a larger movement toward intravascular precision.

 

To be honest, this market was once seen as an offshoot of coronary IVUS. But that’s changing fast. With software-guided interpretation, AI overlays for vessel assessment, and growing evidence of improved patient outcomes, peripheral IVUS catheters are stepping into the spotlight — not just as instruments, but as strategic assets in vascular care.

 

Market Segmentation And Forecast Scope

The peripheral intravascular ultrasound (IVUS) catheter market is shaped by how clinicians use it — from assessing peripheral artery disease to guiding complex vascular interventions. The technology’s growth trajectory is tied closely to procedural settings, frequency of PAD diagnosis, and how hospitals balance imaging precision with cost-efficiency. Segmenting this market helps clarify where innovation and investment are most active.

By Product Type

Peripheral IVUS catheters are generally segmented by frequency, which determines the depth and resolution of imaging.

20 MHz Catheters offer deeper penetration, typically used when assessing larger vessels or where high-resolution detail is less critical. They’re favored in early-stage PAD cases or in patients with significant calcification.

40 MHz Catheters provide much sharper images, ideal for fine-detail visualization in complex or bifurcated lesions. These are more commonly used in critical limb ischemia cases or when planning precision-guided atherectomy.

There are also emerging hybrid catheters that combine IVUS with other modalities — notably Optical Coherence Tomography (OCT) — though these are still in limited adoption due to cost and training requirements.

40 MHz IVUS catheters currently dominate market share , largely due to demand for high-resolution imaging in interventional radiology and vascular surgery. That said, lower-frequency catheters are gaining ground in emerging markets, where affordability and procedural simplicity are higher priorities.

 

By Application

The majority of usage centers on two key clinical scenarios:

Peripheral Artery Disease (PAD): By far the largest application. IVUS is used to assess lesion severity, guide balloon angioplasty or stent placement, and confirm post-procedure outcomes. With PAD diagnoses rising, especially in older adults and diabetics, demand for IVUS-guided care is expanding across both urban and rural vascular centers.

Aneurysm and Venous Interventions: Although a smaller segment, IVUS plays a growing role in monitoring iliac or femoral aneurysms and optimizing venous stent deployment. As chronic venous insufficiency and deep vein thrombosis cases rise, IVUS adoption may increase for lower extremity venous procedures.

Peripheral artery disease accounts for over 68% of the total market revenue in 2024 (inferred).

 

By End User

This segmentation reflects procedural complexity and imaging infrastructure:

Hospitals: The largest end-user group . These settings typically use IVUS during complex endovascular surgeries or hybrid operating room (OR) procedures. Most of the advanced and high-cost IVUS systems are located in these facilities.

Catheterization Labs (Cath Labs): A fast-growing segment. Cath labs use IVUS during real-time angioplasty or stent procedures, especially when fluoroscopy alone is insufficient. Their streamlined workflow and dedicated staff make IVUS integration more efficient.

Ambulatory Surgical Centers (ASCs): Smaller but increasing in relevance. ASCs prefer compact, portable IVUS systems — especially in countries like the U.S., where outpatient vascular procedures are climbing due to payer incentives and scheduling efficiency.

Cath labs are expected to see the fastest CAGR between 2024–2030 , driven by growing procedural volume and rising physician preference for IVUS-based stent optimization.

 

By Region

The regional structure mirrors access to advanced vascular care:

• North America leads in procedural volume, device adoption, and reimbursement.

• Europe emphasizes safety protocols and has high clinical acceptance of IVUS in PAD.

• Asia Pacific is the fastest-growing, driven by aging populations and increased awareness of limb salvage strategies.

• Latin America, Middle East & Africa (LAMEA) is still early-stage but seeing uptake through public-private vascular care programs.

Asia Pacific is expected to register the highest CAGR, especially in India, China, and Japan where vascular disease burdens are growing and hospital infrastructure is improving.

 

Market Trends And Innovation Landscape

Peripheral IVUS catheters are no longer just adjunct tools in vascular procedures — they’re becoming central to how vascular surgeons, radiologists, and cardiologists plan and execute minimally invasive treatments. Over the last few years, the field has moved beyond just catheter design into advanced visualization, AI integration, and hybrid imaging. These shifts are reshaping how providers use IVUS across peripheral interventions.

Higher Resolution, Lower Profile

Device manufacturers are in a race to shrink catheter size while increasing resolution. The newer generation of catheters is designed with thinner profiles and more flexible shafts, enabling navigation through tortuous anatomy without compromising on image quality. This is particularly useful in treating patients with complex peripheral arterial lesions, such as below-the-knee occlusions or chronic total occlusions.

One recent shift? The adoption of dual-frequency catheters , which give physicians the option to switch between penetration depth and image detail during a single procedure. These tools make IVUS more versatile, especially when multiple vessel types are involved.

 

Integration with AI and Decision Support

AI is quietly transforming IVUS interpretation. Advanced software platforms now offer real-time plaque characterization, automated lumen measurements, and even predictive modeling for restenosis risk. This reduces the dependency on operator skill and supports more consistent treatment planning.

In some pilot studies, AI-assisted IVUS platforms have shown reduced procedural time and fewer complications in femoropopliteal interventions. As more clinical validation rolls in, hospitals are expected to integrate AI overlays into their IVUS consoles — especially in settings where vascular specialists are in short supply.

One expert from a major interventional radiology network noted, “The real win with AI in IVUS isn’t just accuracy — it’s reducing variability across different operators.”

 

Software-Based Workflow Optimization

New platforms are also focusing on how IVUS fits into broader procedural workflows. Cloud-connected consoles, integrated with PACS systems and EHRs, allow for real-time imaging review and longitudinal tracking of vessel healing. This is important for chronic PAD patients who require multiple interventions over time.

Several vendors are also offering mobile IVUS consoles , making it easier to use the technology across ORs, cath labs, and even outpatient centers — without investing in redundant hardware.

 

IVUS-OCT Hybrids Are Gaining Attention

While still in early commercial phases, hybrid IVUS-OCT systems are starting to appear in clinical settings. These systems offer both depth (from IVUS) and ultra-high-resolution surface imaging (from OCT) — giving a more complete picture of plaque composition and vessel wall integrity.

Though more commonly used in coronary interventions for now, some European vascular centers are piloting these devices for complex iliac and femoral procedures. Their growth, however, is contingent on cost reductions and training standardization.

 

Peripheral-Specific Innovation

Historically, most IVUS tech was adapted from coronary systems. That’s changing. New platforms are now designed specifically for peripheral vessels — with longer working lengths, ergonomic delivery systems, and presets optimized for femoral, iliac, and tibial arteries.

Some manufacturers are even embedding RFID-based calibration chips in disposable catheters to reduce imaging errors and improve plug-and-play setup in busy surgical environments.

Bottom line: Innovation in the peripheral IVUS market isn’t incremental — it’s ecosystem-wide. From catheter materials to imaging software to AI overlays, every layer is evolving to make intravascular imaging faster, smarter, and more accessible.

 

Competitive Intelligence And Benchmarking

The competitive landscape in the peripheral intravascular ultrasound (IVUS) catheter market is consolidating around a few technically advanced players, regional specialists, and emerging disruptors. While coronary IVUS systems have long been the focus of big imaging players, the peripheral segment is now catching strategic attention due to increasing procedure volume and favorable clinical data.

Boston Scientific

Boston Scientific is one of the most entrenched players in the IVUS space. Their systems are widely adopted in both coronary and peripheral interventions. The company’s strategy in the peripheral market is to offer integrated IVUS consoles and AI-enabled image guidance to support limb salvage procedures. Through acquisitions and internal R&D, they’ve also strengthened their catheter portfolio with longer working lengths suited for lower extremity interventions.

Boston Scientific maintains a broad geographic footprint, with significant penetration in the U.S., Japan, and select European countries. Its partnerships with vascular training institutes and live-case symposiums have helped drive procedural adoption, particularly in underpenetrated outpatient settings.

 

Philips

Philips is aggressively positioning its IVUS offerings — especially after its acquisition of Volcano Corporation. Their systems are known for seamless integration with cath lab workflows and high-definition imaging consoles . In the peripheral segment, Philips has made moves to expand its catheter compatibility, focusing on flexibility and ease of use across complex lesion subsets.

The company’s AI-augmented IVUS platform is gaining popularity among vascular surgeons who prefer intuitive measurement tools and procedural guidance. Philips also stands out for offering remote training modules and simulation-based learning, addressing the steep learning curve that IVUS sometimes presents.

 

Terumo Corporation

Terumo’s strategy in the IVUS market has been more regional and specialized. Its systems are particularly favored in Japan and parts of Southeast Asia, where procedure standardization and imaging protocols are deeply embedded in vascular care. Terumo has invested heavily in catheter innovation, with emphasis on hydrophilic coatings and enhanced steerability.

What differentiates Terumo is its tight integration between IVUS and therapeutic devices, such as atherectomy tools and drug-coated balloons. This bundling approach appeals to health systems looking to streamline device procurement and ensure compatibility.

 

iSchemaView

Although not traditionally an IVUS company, iSchemaView is developing AI-based vascular imaging software that can integrate with IVUS platforms. Their real-time analytics engine, initially used in stroke diagnostics, is now being explored for automated lesion mapping in peripheral arteries . While still in pilot stages, partnerships with hospitals in the U.S. and Germany are pushing this tech closer to market.

If successful, this software layer could provide vendor-neutral image interpretation , reducing reliance on proprietary consoles and enabling broader adoption in cost-sensitive geographies.

 

Canon Medical Systems

Canon is a newer entrant but is leveraging its expertise in ultrasound and CT to create multi-modal vascular imaging systems . Their R&D is focused on developing compact IVUS systems with cloud-sync capabilities, aimed at ambulatory surgical centers and outpatient vascular labs.

Canon’s strategy is to disrupt the low- to mid-tier segment with affordable, workflow-friendly solutions that appeal to growing markets in Asia and Latin America. While not yet a dominant force, the company is gaining visibility through selective collaborations with interventional radiology clinics.

 

Market Position Summary

Boston Scientific and Philips currently dominate the high-end hospital and cath lab segment, driven by imaging performance and procedural trust. Terumo is strong in Asia with a bundled device approach. iSchemaView and Canon are shaping the next phase — software-driven democratization of IVUS and geographic expansion into cost-sensitive environments.

One vascular innovation lead put it this way: “The next battle in IVUS won’t be hardware — it’ll be who controls the platform that tells you what to do with the image.”

 

Regional Landscape And Adoption Outlook

Adoption of peripheral IVUS catheter technology varies significantly across regions — and not just due to availability. Infrastructure, reimbursement frameworks, training access, and clinical culture all shape how widely and effectively IVUS is integrated into peripheral interventions. As the global burden of peripheral artery disease (PAD) rises, this regional divergence is narrowing — but slowly.

North America

North America leads in terms of overall procedural volume, system penetration, and reimbursement alignment. The United States, in particular, accounts for a significant portion of global revenue, driven by a strong installed base of IVUS consoles in both hospitals and outpatient vascular centers. Updated reimbursement codes from the Centers for Medicare & Medicaid Services (CMS) have reinforced IVUS use during peripheral interventions, especially in patients with high-risk limb ischemia or complex plaque morphology.

In addition to reimbursement, clinical societies like the Society for Vascular Surgery (SVS) and the American College of Cardiology (ACC) are actively integrating IVUS guidance into treatment protocols. This has helped normalize usage not just in academic centers but also in community cath labs and ambulatory surgical centers (ASCs).

Canada, while smaller in market size, shows strong public-sector adoption in tertiary centers, particularly for patients undergoing limb salvage or critical vascular reconstructions.

 

Europe

Europe presents a more nuanced picture. Western European countries like Germany, France, and the UK have high procedural standards and are early adopters of image-guided vascular therapy. However, reimbursement policies differ by country and tend to lag behind the U.S. in terms of incentivizing IVUS use.

In Germany, for instance, IVUS is routinely used in specialized vascular centers, often paired with drug-coated balloon therapies. In contrast, southern and eastern European countries face barriers around equipment costs and clinician training. That said, EU-wide funding for PAD management is opening up new pathways for adoption in under-resourced public health systems.

Clinical conservatism plays a role here. Many vascular surgeons still rely on angiography alone, especially when dealing with superficial femoral artery (SFA) lesions. But newer data showing improved outcomes with IVUS guidance is starting to shift this behavior.

 

Asia Pacific

Asia Pacific is the fastest-growing region for peripheral IVUS adoption — and not by a small margin. Countries like Japan, South Korea, China, and India are investing heavily in vascular imaging infrastructure as PAD and diabetes prevalence spike among aging populations.

Japan has been a pioneer in IVUS technology and clinical usage. Peripheral IVUS is embedded in procedural norms across most hospitals, supported by universal healthcare coverage and local manufacturing innovation. South Korea follows a similar trajectory, with rapid adoption in academic and specialty centers.

China and India are currently focused on expanding access. In China, the government is incentivizing public hospitals to integrate vascular imaging to reduce amputation rates. In India, where out-of-pocket spending dominates, IVUS adoption is concentrated in metro hospitals and private cath labs. But domestic manufacturers and compact system innovators are starting to make these technologies more accessible.

Asia Pacific is projected to grow at the highest CAGR between 2024 and 2030 , due to high patient volume and increasing procedural sophistication.

 

Latin America, Middle East & Africa (LAMEA)

This region is at an earlier stage of IVUS adoption. In Latin America, Brazil and Mexico lead due to their relatively better healthcare infrastructure and growing interventional radiology networks. However, high device costs and limited reimbursement limit market expansion beyond private hospitals.

In the Middle East, countries like Saudi Arabia and the UAE are investing in cardiovascular infrastructure as part of broader health reform initiatives. Some major hospitals in Riyadh and Dubai have piloted IVUS-guided limb salvage protocols, particularly for diabetic foot patients.

Sub-Saharan Africa remains largely untapped, with IVUS rarely used outside of high-end private institutions. Infrastructure limitations, training gaps, and lack of funding are key constraints.

That said, tele-imaging platforms and portable IVUS systems could change the game for underserved regions over the next 5–7 years.

 

End-User Dynamics And Use Case

Peripheral IVUS catheter adoption varies widely depending on the clinical setting — and understanding how different end users interact with this technology is key to predicting where the most growth will come from. While hospitals continue to dominate in volume and infrastructure, ambulatory centers and specialized labs are catching up fast, driven by the shift toward outpatient vascular procedures and value-based care.

Hospitals

Hospitals remain the cornerstone of IVUS catheter usage, especially tertiary care centers and academic medical institutions. These environments handle complex vascular cases — from limb salvage procedures to critical limb ischemia — where intravascular visualization plays a key role in pre- and post-intervention planning.

In these settings, IVUS systems are integrated into hybrid operating rooms or interventional suites. Vascular surgeons and interventional radiologists use the technology not only for diagnostic imaging but also for guiding atherectomy, angioplasty, and stent placement in the femoral, iliac, or popliteal arteries.

Beyond technology, hospitals typically have dedicated imaging staff and access to vendor-led training, which lowers the learning curve and ensures procedural consistency.

 

Catheterization Labs (Cath Labs)

Cath labs are one of the fastest-growing segments for peripheral IVUS adoption. While historically focused on coronary interventions, many cath labs — especially in the U.S., Japan, and Germany — now perform high volumes of lower limb procedures. These labs value speed, precision, and repeatable workflows, all of which IVUS supports.

The appeal lies in workflow efficiency . Modern IVUS systems offer plug-and-play functionality, automatic lumen measurement, and integrated reporting — making it easier to conduct multiple image-guided interventions without slowing down daily schedules.

Cath labs in private hospitals and specialty vascular centers are especially aggressive adopters, often leading the way in integrating IVUS into their standard protocols for complex lesion navigation.

 

Ambulatory Surgical Centers (ASCs)

ASCs represent a growing frontier. These outpatient facilities are lean, cost-sensitive, and increasingly handling endovascular procedures that once required hospital admission. The main challenge in this segment is capital investment — IVUS systems, especially high-end ones, don’t come cheap.

But that’s changing. Manufacturers are now offering compact IVUS consoles and mobile platforms designed specifically for ambulatory use. Some systems can be wheeled from one room to another or even shared across affiliated ASCs. This flexibility, coupled with shorter patient recovery times, makes IVUS a compelling addition for facilities looking to elevate their procedural offerings.

Reimbursement incentives in the U.S. have accelerated IVUS integration in outpatient PAD treatment — particularly in high-volume centers focused on limb preservation.

 

Use Case: IVUS in a South Korean Tertiary Hospital

A tertiary hospital in Seoul recently implemented IVUS-guided protocols for femoropopliteal interventions. The vascular surgery team was managing a diabetic patient with advanced PAD and prior stent restenosis. Pre-operative angiography suggested diffuse disease, but lacked detail on plaque morphology.

Using IVUS, the team discovered severe calcification and under-expanded segments in previously placed stents. Based on real-time IVUS imaging, they opted for targeted atherectomy followed by a drug-coated balloon, avoiding unnecessary stent extension. The procedure was completed faster, with better outcomes and no post-operative complications.

According to the lead interventionalist, “Without IVUS, we would’ve gone in blind. It changed the treatment plan entirely.”

This kind of outcome — faster intervention, lower complication rates, and improved vessel healing — is exactly why more vascular teams are integrating IVUS into everyday decision-making.

 

Recent Developments + Opportunities & Restraints

The peripheral IVUS catheter market has experienced a notable uptick in momentum over the past two years. Recent FDA clearances, strategic acquisitions, and platform enhancements have collectively reinforced the value proposition of IVUS in lower extremity interventions. At the same time, new clinical data and evolving regulatory frameworks have laid the groundwork for wider reimbursement, especially in the outpatient space.

Recent Developments (Past 2 Years)

• Philips expanded its peripheral imaging portfolio by launching a next-gen IVUS catheter system with AI-powered lumen detection, aimed specifically at femoral-popliteal interventions. The system is designed to auto-adjust imaging depth in real-time.

• Boston Scientific received FDA clearance for its latest IVUS catheter designed with dual-layer sensors, improving image fidelity during calcified vessel assessment.

• Canon Medical signed a partnership agreement with a U.S. vascular center chain to deploy its mobile IVUS systems across 20 outpatient facilities, indicating growing interest in ambulatory-specific imaging solutions.

• iSchemaView initiated clinical validation trials for its AI-based IVUS plaque detection software in collaboration with three major European vascular surgery departments.

• Terumo introduced a flexible-tip catheter variant specifically designed for below-the-knee lesions, targeting limb salvage procedures in diabetic populations across Asia Pacific.

 

Opportunities

• Rising PAD Burden in Emerging Markets: With diabetes and vascular disease on the rise in countries like India, China, and Brazil, there's a significant opportunity to scale IVUS systems tailored for resource-constrained settings.

• Shift Toward Outpatient Vascular Procedures: As reimbursement models increasingly favor ambulatory care, demand for compact, mobile IVUS systems is expected to rise — particularly in the U.S. and Western Europe.

• AI and Image-Guided Decision Support: The integration of real-time interpretation tools is lowering the technical barrier to IVUS usage, making it more accessible to general interventionalists and not just specialists.

 

Restraints

• High Capital and Operational Costs: IVUS consoles and disposables remain expensive, especially for smaller facilities or those in low-income regions. This limits broader adoption despite clinical benefits.

• Training and Skill Variability: Effective use of IVUS still relies heavily on operator skill and experience. Lack of standardized training or credentialing slows down procedural adoption in new markets.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.1 Billion
Revenue Forecast in 2030	USD 2.0 Billion
Overall Growth Rate	CAGR of 10.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	20 MHz Catheters, 40 MHz Catheters, Hybrid Catheters
By Application	Peripheral Artery Disease, Aneurysm and Venous Interventions, Others
By End User	Hospitals, Catheterization Labs, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, Japan, India, Brazil, Saudi Arabia, etc.
Market Drivers	- Growth in PAD prevalence worldwide - Increasing demand for image-guided interventions - Integration of AI in vascular imaging
Customization Option	Available upon request